TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03223948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 'Optiflow'
Description: High flow nasal oxygen delivery device 'Optiflow'

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 'Optiflow'
Description: High flow nasal oxygen delivery device 'Optiflow'

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 'Optiflow'
Description: High flow nasal oxygen delivery device 'Optiflow'
Study: NCT04435106

Intervention type: DRUG
Intervention: Opaganib
Description: Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care

Intervention type: DRUG
Intervention: Standard of Care
Description: Study participants received Standard of Care

Intervention type: DRUG
Intervention: Standard of Care
Description: Study participants received Standard of Care
Study: NCT04226235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga session
Description: a 1-hour yoga session was completed by all participants following a DVD.
Study: NCT00234455

Intervention type: DEVICE
Group type: OTHER
Intervention: drug eluting-stent
Description: PCI

Intervention type: DEVICE
Group type: OTHER
Intervention: drug-eluting stent
Description: PCI
Study: NCT03951584

Intervention type: OTHER
Intervention: ISSNHL with vertigo
Description: Participants who suffered from ISSNHL with vertigo will be included in this study. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset as primary outcome, to evaluate the damage and prognosis of vestibular function.
Study: NCT03342599

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid Supplement
Description: Alpha lipoic acid ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
Study: NCT02902913

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D2i0
Description: No oleocanthal and no oleacein
Study: NCT05990244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment and Recording
Description: Undergo recording of tumor stiffness during surgery and molecular pathological classification through genetic analysis
Study: NCT03440008

Intervention type: OTHER
Intervention: Dynamic 3D bone motion capture
Description: Two x-ray systems will image the subjects ankle while they walk, allowing us to calculate ankle joint angle and alignment

Intervention type: OTHER
Intervention: Dynamic 3D bone motion capture
Description: Two x-ray systems will image the subjects ankle while they walk, allowing us to calculate ankle joint angle and alignment

Intervention type: DEVICE
Intervention: wedged insole
Description: medial or lateral wedge (appropriate for varus or valgus misalignment) will be applied during 1 data collection session to evaluate effect of wedging on misalignment
Study: NCT03652155

Intervention type: PROCEDURE
Intervention: Orthognathic surgery
Description: Patient's pre and post operative hard and soft tissues will be evaluated retrospectively through the use of con-beam computed tomography imaging for hard tissue evaluation and 3DMd three dimensional photography for soft tissue imaging.
Study: NCT02499744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHFNC
Description: For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.
Study: NCT03869112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Physical activity group will be given a charge 2 FitBit device to monitor their PA specially steps count, step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home-based intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation group
Description: Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
Study: NCT00288145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WOW, Working On Wellness weight management
Description: Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
Study: NCT02902913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg of Ibuprofen
Study: NCT03991364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant gait speed group
Description: The speed of the robot-assisted gait treatment is constantly applied for 5 times a week for 2 weeks.
Study: NCT04582214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MetaNeb® System
Description: The intervention device use in this study is The MetaNeb® System (Hill-Rom; St. Paul, MN). It is an FDA 510k cleared device (k124032), powered by compressed gas, that delivers oscillation and lung expansion (OLE) therapy using both continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP). The device also provides supplemental oxygen when used with compressed oxygen and can deliver aerosol therapy during CPEP and/or CHFO. The therapy is indicated for mobilization of secretions, lung expansion therapy and the treatment and prevention of pulmonary atelectasis. The device also provides supplemental oxygen when used with compressed oxygen.
Study: NCT01143402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02563327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: A rifamycin with activity against Mycobacterium tuberculosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: A rifamycin with activity against Mycobacterium tuberculosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: A fluoroquinolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: A rifamycin with activity against Mycobacterium tuberculosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: An anti-tuberculosis agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: An anti-tuberculosis agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: An anti-tuberculosis agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: An anti-tuberculosis agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: An anti-tuberculosis agent
Study: NCT03991364

Intervention type: OTHER
Group type: OTHER
Intervention: Increasing gait speed group
Description: The speed of the robot-assisted gait treatment is gradually increase for 5 times a week for 2 weeks.
Study: NCT02563327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: An anti-tuberculosis agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: An anti-tuberculosis agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: An anti-tuberculosis agent

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: An essential vitamin
Study: NCT03342599

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose fiber ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
Study: NCT02563327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: An essential vitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine
Description: An essential vitamin
Study: NCT00784121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: Lactic Acid (Dermacyd Breeze)
Study: NCT04031729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
Study: NCT02786407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A for Injection
Description: In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In these studies,patients received placebo administered to 20 injection sites
Study: NCT01795287

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: hyperbaric bupivacaine 10-15 mg i.t.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: hyperbaric bupivacaine 10-15 mg i.t.
Study: NCT02878733

Intervention type: DRUG
Intervention: Albumin
Description: patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
Study: NCT01635634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cupping therapy
Description: Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cupping therapy
Description: Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
Study: NCT01617187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
Study: NCT00211965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate
Description: single IM dose of 200 mcg total conjugate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose IM
Study: NCT01252849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of One iStent through a small temporal clear corneal incision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of Two iStents through a small temporal clear corneal incision
Study: NCT01985230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReActiv8 Implantable Stimulation System implanted and activated.
Study: NCT01252849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of Three iStents through a small temperal clear corneal incision
Study: NCT00734448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-inositol
Description: 2 g twice a day until delivery
Study: NCT00332696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: Octreotide long-acting release (LAR) 30 mg intramuscular injection.
Study: NCT01757574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab infusion
Study: NCT04793074

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transforming nanoparticle dressing
Description: Transforming nanoparticle dressing

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional compression dressing
Description: Conventional compression dressing
Study: NCT02876926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart home-based test for HIV
Description: A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based testing only
Description: A standard home-based HIV test kit.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Reminder letters for clinic-based testing
Description: Letters reminding patients to get tested at a free clinic location
Study: NCT00269542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc and iron folic acid - Intervention
Description: The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
Study: NCT00332696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide (Immediate release)
Description: Immediate-release Octreotide supplied in 100 µg/mL ampules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
Study: NCT00638963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles
Study: NCT03586817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: 75 mcg during the anesthesia
Study: NCT00269542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron Folic Acid alone - Placebo
Description: The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
Study: NCT03586817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant
Description: 150 mg during the anesthesia
Study: NCT02403596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exacyl®
Study: NCT02654171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
Study: NCT03185403

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: in the paravertebral block , the catheter was placed under ultrasound echography , at the right thoracic T4/T5 level

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural block
Description: in the epidural block the catheter was inserted without echography , at T4/T5 level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Study: NCT04629859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mandibular setback and maxillary advancement
Description: 12 patients will undergo mandibular setback and maxillary advancement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mandibular setback
Description: 12 patients will undergo mandibular setback
Study: NCT01692314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Study: NCT01763749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Closone
Description: Closone 75mg/100mg, 4weeks, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix with Astrix
Description: Plavix 75mg with Astrix 100mg, 4weeks, PO
Study: NCT02053129

Intervention type: OTHER
Group type: OTHER
Intervention: TB screening Questionnaire
Description: All subjects will be screened with the questionnaire which assesses TB symptoms.

Intervention type: OTHER
Group type: OTHER
Intervention: TB screening Questionnaire
Description: All subjects will be screened with the questionnaire which assesses TB symptoms.

Intervention type: OTHER
Group type: OTHER
Intervention: Sputum smear and culture (only in HIV negative women who are symptomatic)
Description: specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
Study: NCT03977701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological treatment
Description: The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological treatment
Description: The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonological treatment
Description: The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.
Study: NCT00332696

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiologic saline solution
Study: NCT02916264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: a scalp block
Description: Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
Study: NCT03507582

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Distraction
Description: This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Distraction
Description: This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
Study: NCT04409834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin IV
Description: Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg
Description: Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin SC
Description: Heparin 5,000 units administered subcutaneous three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg SC
Description: Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)